ADI-PEG 20 in Combination With Gemcitabine and Docetaxel After Progression on Frontline Therapy in Non-small Cell and Small Cell Lung Cancers

NCT05616624 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

31

Enrollment

OTHER

Sponsor class

Conditions

Non Small Cell Lung Cancer
Non-small Cell Lung Cancer
Small-cell Lung Cancer
Small Cell Lung Carcinoma

Interventions

DRUG: ADI-PEG 20
DRUG: Gemcitabine
DRUG: Docetaxel

Sponsor

Washington University School of Medicine

Collaborators

[object Object]